Terms: = Liver cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Prognosis
180 results:
1. Single-cell data revealed exhaustion of characteristic NK cell subpopulations and T cell subpopulations in hepatocellular carcinoma.
Cui Z; Li H; Liu C; Wang J; Chen C; Hu S; Zhao X; Li G
Aging (Albany NY); 2024 Apr; 16(7):6550-6565. PubMed ID: 38604154
[TBL] [Abstract] [Full Text] [Related]
2. Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma.
Ohama H; Hiraoka A; Tada T; Hirooka M; Kariyama K; Hatanaka T; Tani J; Takaguchi K; Atsukawa M; Itobayashi E; Nishimura T; Tsuji K; Tajiri K; Ishikawa T; Yasuda S; Toyoda H; Fukunishi S; Ogawa C; Kakizaki S; Shimada N; Naganuma A; Kawata K; Kosaka H; Kuroda H; Matono T; Yata Y; Ochi H; Tada F; Nouso K; Morishita A; Itokawa N; Okubo T; Arai T; Tsutsui A; Nagano T; Yokohama K; Nishikawa H; Imai M; Koizumi Y; Nakamura S; Iijima H; Kaibori M; Hiasa Y; Kumada T;
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2042. PubMed ID: 38577725
[TBL] [Abstract] [Full Text] [Related]
3. Fibroblast activation protein promotes progression of hepatocellular carcinoma via regulating the immunity.
Wang X; Niu R; Yang H; Lin Y; Hou H; Yang H
Cell Biol Int; 2024 May; 48(5):577-593. PubMed ID: 38501437
[TBL] [Abstract] [Full Text] [Related]
4. Primary hepatic Castleman disease.
Danis HE; Keenan C; Schaber J; Grasso SL
BMJ Case Rep; 2024 Mar; 17(3):. PubMed ID: 38479827
[TBL] [Abstract] [Full Text] [Related]
5. Exosomal ncRNAs: Multifunctional contributors to the immunosuppressive tumor microenvironment of hepatocellular carcinoma.
Huang Q; Zhong X; Li J; Hu R; Yi J; Sun J; Xu Y; Zhou X
Biomed Pharmacother; 2024 Apr; 173():116409. PubMed ID: 38460375
[TBL] [Abstract] [Full Text] [Related]
6. REXO2 up-regulation is positively correlated with poor prognosis and tumor immune infiltration in hepatocellular carcinoma.
Zhang T; Zhang R; Zhang Z; Li D; Guo X; Zhang Z; Zhu X; Tan S
Int Immunopharmacol; 2024 Mar; 130():111740. PubMed ID: 38401464
[TBL] [Abstract] [Full Text] [Related]
7. Neoadjuvant therapies in resectable hepatocellular carcinoma: Exploring strategies to improve prognosis.
Ma YN; Jiang X; Song P; Tang W
Biosci Trends; 2024 Mar; 18(1):21-41. PubMed ID: 38382930
[TBL] [Abstract] [Full Text] [Related]
8. Establishment and Validation of Novel Prognostic Subtypes in Hepatocellular Carcinoma Based on Bile Acid Metabolism Gene Signatures Using Bulk and Single-Cell RNA-Seq Data.
Qu Y; Gong X; Zhao Z; Zhang Z; Zhang Q; Huang Y; Xie Q; Liu Y; Wei J; Du H
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255993
[TBL] [Abstract] [Full Text] [Related]
9. The Association of Immune Cell Infiltration with Metastasis Location in De Novo Metastatic Triple Negative Breast cancer: A Multicenter Cross-Sectional Study in Indonesia.
Tenggara JB; Rachman A; Prihartono J; Lisnawati L; Panigoro SS; Heriyanto DS; Steven R; Tandarto K; Juanputra S; Sudoyo AW
Acta Med Indones; 2023 Oct; 55(4):376-384. PubMed ID: 38213050
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic and immunological role of adaptor related protein complex 3 subunit mu2 in colon cancer.
Jin Q; Feng J; Yan Y; Kuang Y
Sci Rep; 2024 Jan; 14(1):483. PubMed ID: 38177168
[TBL] [Abstract] [Full Text] [Related]
11. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal cancer after Treatment Termination.
Simmons K; Thomas JV; Ludford K; Willis JA; Higbie VS; Raghav KPS; Johnson B; Dasari A; Kee BK; Parseghian CM; Lee MS; Le PH; Morelli MP; Shen JP; Bent A; Vilar E; Wolff RA; Kopetz S; Overman MJ; Morris VK
Cancer Res Commun; 2023 Dec; 3(12):2510-2517. PubMed ID: 38085001
[TBL] [Abstract] [Full Text] [Related]
12. NPC1 promotes autophagy with tumor promotion and acts as a prognostic model for hepatocellular carcinoma.
Xu J; Chen F; Zhu W; Zhang W
Gene; 2024 Mar; 897():148050. PubMed ID: 38042211
[TBL] [Abstract] [Full Text] [Related]
13. Metastases and treatment-resistant lineages in patient-derived cancer cells of colorectal cancer.
Fujino S; Miyoshi N; Ito A; Hayashi R; Yasui M; Matsuda C; Ohue M; Horie M; Yachida S; Koseki J; Shimamura T; Hata T; Ogino T; Takahashi H; Uemura M; Mizushima T; Doki Y; Eguchi H
Commun Biol; 2023 Nov; 6(1):1191. PubMed ID: 37996567
[TBL] [Abstract] [Full Text] [Related]
14. Identification of cancer-associated fibroblasts signature for predicting the prognosis and immunotherapy response in hepatocellular carcinoma.
Ye J; Tian W; Zheng B; Zeng T
Medicine (Baltimore); 2023 Nov; 102(45):e35938. PubMed ID: 37960718
[TBL] [Abstract] [Full Text] [Related]
15. Bioinformatics identification of a T-cell-related signature for predicting prognosis and drug sensitivity in hepatocellular carcinoma.
Wang D; Ding D; Ying J; Qin Y
IET Syst Biol; 2023 Dec; 17(6):366-377. PubMed ID: 37935646
[TBL] [Abstract] [Full Text] [Related]
16. Seven chromatin regulators as immune cell infiltration characteristics, potential diagnostic biomarkers and drugs prediction in hepatocellular carcinoma.
Chai JW; Hu XW; Zhang MM; Dong YN
Sci Rep; 2023 Oct; 13(1):18643. PubMed ID: 37903974
[TBL] [Abstract] [Full Text] [Related]
17. Overexpression of SH2D1A promotes cancer progression and is associated with immune cell infiltration in hepatocellular carcinoma via bioinformatics and in vitro study.
Xiang QM; Jiang N; Liu YF; Wang YB; Mu DA; Liu R; Sun LY; Zhang W; Guo Q; Li K
BMC Cancer; 2023 Oct; 23(1):1005. PubMed ID: 37858067
[TBL] [Abstract] [Full Text] [Related]
18. Clinical implications of RAB13 expression in pan-cancer based on multi-databases integrative analysis.
Zhang XD; Liu ZY; Luo K; Wang XK; Wang MS; Huang S; Li RF
Sci Rep; 2023 Oct; 13(1):16859. PubMed ID: 37803063
[TBL] [Abstract] [Full Text] [Related]
19. Identification of M2-like macrophage-related signature for predicting the prognosis, ecosystem and immunotherapy response in hepatocellular carcinoma.
Feng Q; Lu H; Wu L
PLoS One; 2023; 18(9):e0291645. PubMed ID: 37725627
[TBL] [Abstract] [Full Text] [Related]
20. The m
Ma E; Li J; Shen C; Gu Y; Zhang X; Li L; Zhao J; Wang Z
Front Immunol; 2023; 14():1227593. PubMed ID: 37691948
[TBL] [Abstract] [Full Text] [Related]
[Next]
